Immutep
Immutep is an Australian-French company built on the immune checkpoint LAG-3, whose soluble LAG-3 protein eftilagimod alpha is in the phase 3 TACTI-004 trial with pembrolizumab and chemotherapy in first-line non-small-cell lung cancer.
Overview
Immutep, listed in Sydney and on Nasdaq and with research in Paris, develops therapies around LAG-3, a checkpoint discovered by its scientific founder. Its lead, eftilagimod alpha (efti), is a soluble LAG-3 protein that activates antigen-presenting cells through MHC class II rather than blocking a checkpoint, and is combined with PD-1 antibodies and chemotherapy; after phase 2 results in lung and head and neck cancer it began the phase 3 TACTI-004 trial in first-line non-small-cell lung cancer in 2025. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +6
- 24-month regulatory events +6
- registry trials +30
Similar pages
not linked directly; found by shared links- CompanyAP Biosciences
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyEpicentRx
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyVyriad
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyAveta Biomics
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyQBiotics
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyRakuten Medical
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanySTCube
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.